Background: Many variants detected after the Wuhan-Hu-1 reference was able to develop the resistance against the neutralizing antibodies induced by the vaccine and may cause false-negative results in the diagnostic test. Novel variant B1.617 was detected in India and the Covid-19 cases hiked to their maximum; forcing the government towards approving a new vaccine for restricted use in an emergency situation to cover a maximum population.

Aims: This review looks at the efficacy, safety, and economical aspects of vaccines that have been authorized in India.

Materials and methods: Wide-ranging assessment and analysis of accessible resources on the online database.

Results: The rAd26-s & rAd5-s demonstrate high efficacy as well as safety, followed by BBV152 and AZD1222. Various combinations of the vaccines with different platforms or vectors may induce a wide range of immunity than a specific one. As per the economical aspect, AZD1222 is more economical than the other two currently approved in India.

Conclusion: There is a lack of a clear endpoint to measure the efficacy of the vaccine so epidemiological studies with thehuge number of populations are required which may predict the perfect endpoint for efficacy measurement. Until then, inoculation with locally accessible vaccines and self-awareness about disease transmission prevention are the main options for reducing fatalities, protecting the healthcare system, and eventually disease control.

Key Words: Covid-19, Immunization, Vaccine Efficacy, Vaccine Safety.